Blade Air Mobility Inc - Ordinary Shares - Class A Stock News

Keystone is expected to generate approximately $65 million of revenue and approximately $13 million of Adjusted EBITDA (1) in the full-year 2025, with revenue expected to grow more than 50% in 2025 versus 2024 Acquisition follows multi-year partnership between Strata and Keystone whereby Keystone has successfully recovered hundreds of organs on behalf of Strata customers $124 million acquisitio...

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), today confirmed that the previously announced change of its legal name to Strata Critical Medical, Inc is expected to occur this week. The change is intended to reflect the Company's plan to focus on providing mission critical logistics and medical services to hospitals and healthcare ...

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), a technology-powered air mobility platform, today announced that Will Heyburn, Chief Financial Officer, will present at the Oppenheimer 28th Annual Technology, Internet & Communications Conference on Monday, August 11, 2025 at 2:55pm ET. A webcast of the event will be available at the ...

It's been quite the week for Blade Air Mobility Inc. NASDAQ: BLDE. On August 4, Blade and Joby Aviation Inc. NYSE: JOBY announced the sale of Blade's passenger mobility business to Joby for up to $125 million.

Blade (BLDE) Q2 Revenue Jumps 10%

Blade Air Mobility sold its passenger/UAM division to Joby Aviation, shifting focus to medical organ transport and rebranding as Strata Critical Medical. The deal improves Blade's capital position but sacrifices the higher-growth air taxi opportunity, disappointing original investment expectations. Strata now controls 30% of the organ logistics market, with strong growth, solid profitability, a...

Blade Air Mobility, Inc. (NASDAQ:BLDE ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Mathew Schneider - Vice President of Investor Relations & Strategic Finance Melissa M. Tomkiel - President, General Counsel & Corporate Secretary Robert S.

Medical revenue increased 17.6% year-over-year in Q2 2025 Net loss improved by $7.6 million versus the prior year to $(3.7) million in Q2 2025; Adjusted EBITDA improved by $2.2 million versus the prior year to $3.2 million in Q2 2025 (1) Blade Passenger division to be sold to Joby Aviation for up to $125 million; Blade's Medical division will remain a standalone public company, rebrand as Strat...